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Abstract

The number of truly drug-resistant hypertensive patients is small if careful attention is paid to blood pressure
measurement, lifestyle measures are instituted and treatment is adjusted as required. An effective drug
combination for the treatment of resistant hypertension is an ACE inhibitor (or angiotensin II receptor
blocker), a calcium channel blocker and a thiazide-like diuretic, with possibly the addition of a fourth drug.
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Key points
• Around half of patients on antihypertensive treatment have
blood pressures above target. However, only about one in
three of these patients are truly treatment resistant.
• Apparent treatment resistance can be avoided by careful
attention to blood pressure measurement, avoiding
therapeutic inertia, careful choice of an effective and 
well-tolerated regimen, and by working together with the
patient to implement lifestyle measures and maximise
compliance with an antihypertensive regimen.
• Some old drugs retain their usefulness in the setting of
resistant hypertension, and newer innovations have not
shown unequivocal benefit.
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R

esistant hypertension is generally defined as the situation that
exists when blood pressure remains above target (usually
140/90 mmHg, or 130/80 mmHg in individuals with diabetes)
despite the use of at least three antihypertensive drugs in
maximum tolerated doses. Resistant hypertension is but one of many
reasons for treatment failure in hypertension.
Hypertension is common and has serious consequences, and
blood pressure is often above desired levels in patients treated for
the condition. However, most of these inadequately treated patients
will not be truly resistant to antihypertensive drug treatment.
The World Health Organization estimates that around one in
three deaths globally (about 17 million in 2008) are from cardiovascular disease, with the majority of these (9.4 million) being attributable
to hypertension.1 Hypertension is held responsible for around 45%
of deaths due to heart disease and about 51% of deaths due to stroke.
Worldwide, about 40% of adults over 25 years of age are hypertensive,
with the highest prevalence in low-income countries.
In Australia, about 30% of those aged 25 years and older are
hypertensive, a prevalence that is similar to that reported in the
USA.2,3 A recent study of people aged over 60 years in Melbourne
and rural Victoria showed that 52% of those on antihypertensive
treatment had blood pressures of more than 140/90 mmHg.4 The
most recent National Health and Nutrition Examination Survey
(NHANES) in the USA found that 48% of hypertensive patients
had blood pressure greater than 140/90 mmHg on treatment.3 Thus
only half of treated patients are adequately controlled. Observational
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The number of truly drug-resistant hypertensive patients
is small if careful attention is paid to blood pressure
measurement, lifestyle measures are instituted and treatment
is adjusted as required. An effective drug combination for the
treatment of resistant hypertension is an ACE inhibitor (or
angiotensin II receptor blocker), a calcium channel blocker
and a thiazide-like diuretic, with possibly the addition of a
fourth drug.

data in the general population indicate that control of blood pressure
is the key factor in reducing the excess mortality risk in this group,
confirming results from numerous prior randomised trials that
were more selective in their inclusion criteria.5
This article discusses the criteria for hypertension being considered treatment resistant, the reasons this occurs and how patients
can be treated. The flowchart on this page summarises the diagnosis
and treatment of resistant hypertension.

Resistant hypertension: diagnosis and management
Hypertensive patient, measured clinic BP
>140/90 mmHg

Was the correct technique
(e.g. correct cuff size)
used to measure BP?

No

Repeat
with correct
technique

Criteria for determining treatment resistance
Criteria for determining whether hypertension is resistant to treatment are relative, decided by consensus and have changed over time.
Key elements contributing to the decision are the level of blood
pressure that should be attained and the minimum treatment that
should be prescribed (and taken) before hypertension is declared to
be treatment resistant.
Initial suggestions were that blood pressure should be clearly
above target, and a level of 150/100 mmHg was chosen arbitrarily.6
Recent consensus is that any blood pressure above target is sufficient
to indicate resistance. Broad agreement exists for the use of at least
three drugs, one of which should be a diuretic, before hypertension
can be considered to be treatment resistant.6,7
The most detailed recommendation comes from the UK National
Institute for Health and Care Excellence (NICE) guidelines for the
clinical management of primary hypertension in adults.8 These
guidelines offer explicit directions for initiation and escalation of
treatment, with the recommendation that a three-drug regimen
includes an ACE inhibitor or angiotensin II receptor blocker, a
calcium channel blocker and a thiazide-like diuretic.

Reasons for apparent antihypertensive drug resistance
Incorrect blood pressure measurement
The technique and method of measuring blood pressure is important
to ensure that blood pressure is truly above target.
Measuring blood pressure in obese subjects can be quite a challenge.9 The use of a cuff that is too small in obese patients results in
overestimation of blood pressure.10 Occasionally, it may not be
physically possible to have an appropriately wide cuff in a short,
obese arm; in such a situation, the use of a cuff around the forearm
can provide a solution.10
Typically, office blood pressure has been utilised to define
treatment resistance. The recognition of ‘white-coat’ hypertension
in other contexts prompted the use of ambulatory blood pressure
to evaluate resistant hypertension. One study found that patients
with elevated blood pressure in the office but not on ambulatory
measurements (i.e. white-coat hypertension) had similar rates of
cardiovascular events to those whose blood pressure had fallen to
acceptable levels on treatment.11 Those who had elevated blood
pressure on ambulatory measurements as well as office measurements
(true resistant hypertension) had more cardiovascular events than
those with acceptable
blood pressure
treatment,1:43
whereas
those4
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with elevated ambulatory but adequate office pressure (masked

Yes

Is daytime ambulatory
BP >135 mmHg?

No

Patient has
‘white-coat’
resistance

Yes

Is the patient
taking an effective
three-drug

No

Yes

Use drugs with
independent
mechanisms and
include a diuretic
(e.g. ACE inhibitor
or ARB + calcium
channel blocker +
thiazide-like
diuretic)

Patient has true
resistant hypertension

Is there an underlying
cause?
• Consider and exclude
causes of secondary
hypertension, including
drugs (may include
over-the-counter and
complementary
medicines)

Yes

• If possible,
eliminate
cause
(e.g. cease
offending drug)
• Consider
specialist
referral

No

What else can be done for the patient?
• Review implementation of lifestyle measures
• Consider a fourth drug
• Deal with other risk factors
• Refer if patient remains treatment resistant or there is
uncertainty about drug regimen or investigation of underlying
cause
Abbreviations: ACE = angiotensin converting enzyme; ARB = angiotensin II
receptor blocker; BP = blood pressure.
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RESISTANT HYPERTENSION CONTINUED

1. Causes of secondary hypertension
• Obstructive sleep apnoea (especially common in resistant
hypertension)
• Primary aldosteronism
• Cushing’s syndrome
• Renal parenchymal disease
• Renal artery stenosis
• Phaeochromocytoma
• Drugs or chemicals (see Box 2)

 ypertension) had an intermediate rate of cardiovascular events.11
h
Other studies have reported similar findings.12,13 Thus a strong case
can be made for measuring ambulatory pressure when resistant
hypertension is suspected.
If ambulatory blood pressure is unavailable, home blood pressure
measurement is a reasonable substitute. It should be noted that the
ambulatory equivalent of a clinic blood pressure of above
140/90 mmHg is a daytime ambulatory blood pressure of above
135/85 mmHg.14 Using a cut-off level of 140/90 mmHg on ambulatory
measurements will misclassify patients as being adequately treated
when they are not.
Treatment inertia
Agreement about the minimum treatment requirement before
hypertension is declared resistant discloses a large group of patients
who are neither controlled nor on a three-drug regimen. For the
most part, these circumstances indicate treatment inertia, a problem
to which both patients and doctors contribute. A recent study conducted in Melbourne and rural Victoria found that just over half of
treated hypertensive subjects had blood pressures of 140/90 mmHg
or higher and nearly 80% of these were on one or two antihypertensive
drugs.4 Of even greater concern, only 20% of patients whose blood
pressure on treatment was 160/100 mmHg or higher were on three
drugs. Uncontrolled hypertension often has more to do with treatment inertia than with treatment resistance.
Drug side effects and noncompliance
At times patients complain of intolerable drug side effects, making
it difficult to find a regimen that is both effective and well tolerated.
If many medications elicit symptoms suggestive of hypotension
it would be important to consider and exclude ‘white-coat
resistance’.
Occasionally, it may have to be accepted that, at least from the
patient’s perspective, the cost in side effects is not worth the gain.
The patient might decide that daily symptoms incurred in the treatment of an asymptomatic condition are unacceptable when there is
no certain benefit, only a reduction in the risk of a possible future
cardiovascular event.
Another reason for
apparent
drug resistance
is nonadherence
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prescribed treatment. Failure to take medications as prescribed is

common across a wide range of illnesses.15 Compliance may peak
around the time of an outpatient appointment, making it more difficult
to detect noncompliance.16 Dosing frequency and regimen complexity
contribute to limited persistence with prescribed treatment.17
A range of solutions make good sense: for example, better
communication between doctor and patient, patient education and
involving the patient in their own management (such as home blood
pressure measurement).15,18 However, empirical evidence of efficacy
of these approaches is limited. A recent systematic review recommends
the simplification of dosing regimens to improve compliance and
suggests that education alone is not particularly effective.19

What characterises the treatment-resistant patient?
Excluding hypertensive patients with ‘white-coat resistance’, thera
peutic inertia and noncompliance leaves a core of patients whose
blood pressure is genuinely resistant to drug treatment. The size of
the problem is difficult to estimate.
One study determined the incidence of resistance in 205,750
patients with incident hypertension and found that 1.9% developed
resistant hypertension within a median of 1.5 years from initial
treatment (0.7 cases per 100 person-years of follow up).20 Prevalence
has been estimated from population studies where treatment details
are difficult to ascertain and from large clinical trials where participants may not be representative of the wider population. A recent
review pooled data from several studies (including epidemiological
studies and controlled trials) to report a prevalence of resistant
hypertension of 14.8% in treated hypertensive patients.21
Those with resistant hypertension are more likely to smoke and
drink alcohol to excess; more likely to be older, male and obese; and
more likely to have diabetes, target organ damage and cardiovascular
disease or a high predicted cardiovascular risk.22-25 Adverse cardiovascular outcomes and mortality are increased in patients with resistant
hypertension, providing a strong imperative to gain control of blood
pressure.20,21,26,27

Secondary hypertension, including drug-induced
hypertension
Secondary hypertension is more common in patients with resistant
hypertension than in unselected patients.7 The causes of secondary
hypertension that should be considered are listed in Box 1.7,28
Resistant hypertension has a strong association with sleep apnoea,
but the response to treatment is variable and meta-analyses report a
modest average fall in blood pressure with CPAP.7,28,29 Hyperaldo
steronism and renal parenchymal disease are also common in patients
with resistant hypertension.7
Other important causes of secondary hypertension are the drugs
that raise blood pressure or interfere with the efficacy of antihypertensive drugs (Box 2). Common examples are NSAIDs, sympathomimetics (nasal decongestants, appetite suppressants), steroids (oral
contraceptives, glucocorticoids) and related agents (e.g. liquorice,
which inhibits 11beta-hydroxysteroid dehydrogenase allowing cortisol
to activate mineralocorticoid receptors). Several of the new anticancer
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drugs (and especially the antivascular endothelial growth factor
therapies) can affect blood pressure.30

What can be done for treatment-resistant patients?
Lifestyle adjustment
Obesity, moderate alcohol consumption and excessive intake of salt
all increase blood pressure. Strategies to lose weight and reduce the
intakes of alcohol and salt help lower blood pressure. The challenge
for the patient and the treating physician has been the implementation
and maintenance of lifestyle change. Salt reduction appears to be
particularly effective in the setting of treatment resistance.31
Pharmacological treatment
Optimising the antihypertensive regimen is important for patients with
resistant hypertension. The use of certain drugs in combination is more
effective than combinations of other drugs.32,33 An ACE inhibitor (or
angiotensin II receptor blocker), a calcium channel blocker and a diuretic,
as recommended by NICE, is an effective combination.8 Combinations
of an ACE inhibitor and an angiotensin II receptor blocker (dual renin–
angiotensin–aldosterone blockade) or an ACE inhibitor and a beta
blocker are less than additive in lowering blood pressure.
The addition of a fourth drug is reasonable once the best three-drug
combination has been established for the individual patient. There is
a paucity of evidence for effective add-on medications in this setting.
After early promising results, the endothelin antagonist darusentan
has been shown to be relatively ineffective at lowering ambulatory
blood pressure.34 The only drugs for which there is evidence for efficacy
from randomised controlled trials in the setting of resistant hypertension are spironolactone and minoxidil.35-37 Minoxidil is effective
but difficult to use: its use is regularly accompanied by fluid retention
and tachycardia that may need to be combated by other drugs (diuretics
and beta blockade), and it can cause hirsutism.37
Another approach that has been shown to be useful in a randomised
trial is sequential nephron blockade (the concurrent use of diuretics
that act at different sites of the renal tubule).38 The obvious hazard with
this approach is volume depletion and renal impairment.
Several other drugs can be used to lower blood pressure but have
not been trialled in the setting of resistant hypertension. These
include vasodilators such as hydralazine, alpha adrenergic receptor
antagonists and centrally acting antihypertensive drugs.
Device-based procedures
Two device-based procedures have been used in recent years to treat
patients with resistant hypertension: renal denervation and carotid-baroreceptor nerve stimulation. At present, neither procedure
can be unequivocally recommended. Deployment should be
performed in specialised units, preferably in clinical trials that will
help define the place of these new treatments.

2. Hypertension induced by drugs or chemicals
• Sympathomimetic agents (weight-loss pills, decongestants,
amphetamine and amphetamine-like substances, cocaine,
herbal agents such as ephedra [ma huang])
• Steroids and related substances
– oral contraceptive pills and exogenous oestrogen
– exogenous glucocorticoids and mineralocorticoids
– liquorice (allows cortisol to activate mineralocorticoid receptors)
• Antidepressants
• Alcohol
• Immunosuppressants (especially cyclosporin)
• Erythropoietin
• Anticancer drugs (especially anti-VEGF drugs)
Abbreviation: VEGF = vascular endothelial growth factor.

very substantial efficacy: a fall of 27/17 mmHg at 12 months in the
former study and 32/12 mmHg at six months in the latter.39,40 Unfortunately, the keenly awaited double-blind, sham-controlled study
(Symplicity-3) has recently reported disappointing results: a
2.39 mmHg between group difference for office blood pressure and
a 1.96 mmHg between group difference in 24-hour ambulatory
systolic blood pressure.41 Whether the apparent difference in efficacy
in these three studies is a result of more rigorous evaluation of efficacy
in Symplicity-3, differences in the patient population enrolled in the
three studies or the experience of the operators is hotly debated.
Carotid-baroreflex activation
Baroreflex activation is more difficult to deploy than renal denervation
and is not yet generally available. Initial promising results in a nonrandomised study42 were followed by less impressive results in a
randomised blinded study (the device was implanted but not switched
on in the control group). In this study, baroreflex activation resulted
in no significant difference between treated subjects and controls
(16 ± 29 mmHg and 9 ± 29 mmHg, respectively).43

Summary
If careful attention is paid to measuring blood pressure, instituting
lifestyle measures and adjusting treatment as required, the number
of truly drug-resistant hypertensive patients is small. A second look
for underlying causes of hypertension is warranted in this group,
including in particular the possibility that concurrent treatment is
contributing to elevated blood pressure. Some old drugs retain their
usefulness in the setting of resistant hypertension, and newer innovations have not shown unequivocal benefit. 
CT
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